Scientists speak of a historic moment in the fight against Alzheimer's disease. An experimental drug significantly slowed mental decline in patients who were still at an early stage of senile dementia.
The injectable drug lekanemab stops the development of senile dementia, which until today is considered incurable. In a study of over 1,800 patients, lecanemab slowed disease progression by approximately 25%. This drug, developed by pharmaceutical giants in the US and Japan, targets the protein plaques that form in the brain, which cause the symptoms. confirmation of a long-standing theory that removing beta-amyloid proteins from the brain can delay the development of an incurable and insidious disease. Experts call these studies a huge breakthrough, but emphasize that it was achieved only in patients with early stages of Alzheimer's disease.
The drug slowed down the development of ALS
Therefore, it is not yet possible to talk about the development of a universal drug for all patients. In the near future, this drug will begin to be considered by regulatory authorities in the US and the UK, and it is not yet clear when exactly it will be approved and allowed for widespread use. (READ MORE)